About Us
Established in 2015 | Pioneering a New Era in Regenerative Medicine
U-NEURON Biomedical is an innovative biotechnology company dedicated to regenerative medicine and exosome applications. Centered on proprietary amniotic fluid stem cell (AFSC) technology, combined with exosome development and functional biologics, U-NEURON has built a comprehensive business layout spanning therapeutics, cosmeceuticals, and health supplements. The company is committed to establishing a world-leading Exosome Design House × Foundry business model, accelerating the transition of regenerative medicine from laboratory to market through integrated design, manufacturing, and application.
| Number | Patent technology title | Patent numbers and status in various countries |
|---|---|---|
| 01 | Pharmaceutical compositions containing amniotic fluid stem cell spheroids and uses thereof in treating urinary incontinence | ߇鰟缠TW: I751692 B (Granted) ߇갟縠US: 11766460 B2 (Granted) ߇谟糠CN: 202010951931.5 (App) |
| 02 | Treatment of erectile dysfunction using amniotic fluid mesenchymal stem cells | ߇갟縠US: 18/1873344 (App) / ߇鰟缠TW: 112110504 (App) / ߇氟纠AU: 2023240916 (App) ߇谟禠CA: 3254662 (App) / ߇갟纠EPC: 23773862.0 (App) / ߇ﰟ絠JP: 2024-555918 (App) ߇ట締KR: 10-2024-7031222 (App) / ߇Ⱏ羠MY: PI2024005419 (App) / ߇谟糠CN: 202380028465.5 (App) |
| 03 | Uses of amniotic fluid cell secretome in treating dry eye disease | ߇鰟缠TW: I856252 B (Granted) / ߇谟糠CN: 202210014790.3 (Granted) / ߇갟纠EPC: EP 4098270 B2 (Granted) ߇ﰟ絠JP: 7580130 B2 (Granted) / ߇ట締KR: 10-2794579 B1 (Granted) / ߇氟纠AU: 2022203692 (Granted) ߇갟縠US: 18/772,790 (App) |
| 04 | Compositions containing amniotic fluid stem cells or derivatives thereof and methods of use | ߇鰟缠TW: I867713 B (Granted) / ߇谟笠SG: 11202501260U (App) ߇갟縠US: 19/106,218 (App) / ߇谟糠CN: 202380061896.1 (App) ߇갟纠EPC: 23782731.6 (App) / ߇Ⱏ羠MY: PI2024005419 (App) |
| 05 | Freeze-dried stem cell powder derived from Cervidae, preparation method, uses, and compositions thereof | ߇鰟缠TW: M667337 (Utility Model Granted) / ߇鰟缠TW: 113142143 (App) ߇갟縠US: 19/378289 (App) / ߇Ⱏ羠MY: I2025006851 (App) |
| 06 | Mixed conditioned medium or exosome compositions derived from Cervidae stem cells of different origins, preparation methods, and uses thereof | ߇갟縠US: 63/994,036 (Provisional App) |
| 07 | Method for producing function-enhanced exosomes using low-concentration resveratrol derivative (Piceatannol) | ߇갟縠US: 63/994,110 (Provisional App) |
%
of the team members hold a master’s degree or higher, including five PhD-level researchers.
senior technical professionals with an average of over 14 years of industry experience.
Our Business
U-NEURON Biomedical drives long-term corporate expansion through a Dual-Engine Growth Model. On one hand, through drug development, we continuously accumulate high-value patents and core technologies, focusing on UA002 and UB003 stem cell/exosome drug candidates to capture high-barrier, high-growth therapeutic markets. On the other hand, through the i-ExoCraft® Exosome Design House, we rapidly translate R&D achievements into skincare, dietary supplements, pet care, and other diverse sectors, accelerating commercialization and market expansion.
With R&D as the core and commercialization as the extension, the two engines create a parallel development model of technology-driven innovation and revenue growth, building a sustainable and scalable biomedical platform.
Market Strategy
Pioneering Regenerative Medicine: A New Era of Amniotic Fluid Cells and Exosomes